First Patient Dosed in Phase II Renal Cancer Theranostics Study
Go back to First Patient Dosed in Phase II Renal Cancer Theranostics Study| TRANS-LUX CORPORATION (NASDAQ: TLX) | Delayed: 11.97 -0.03 (0.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.00 | 52 Week High | $2.18 | |||
| Open | $12.14 | 52 Week Low | $0.30 | |||
| Day High | $12.15 | P/E | N/A | |||
| Day Low | $11.96 | EPS | $-3.32 | |||
| Volume | 76,437 | |||||
